AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
AAPL   320.73 (+0.88%)
MSFT   182.44 (-0.44%)
FB   228.70 (+1.60%)
GOOGL   1,433.17 (-0.02%)
CGC   16.06 (-7.54%)
BABA   204.82 (-1.24%)
MU   46.77 (-2.38%)
GE   6.70 (+1.98%)
TSLA   877.85 (+5.13%)
AMD   53.34 (-0.86%)
T   31.08 (+0.71%)
ACB   13.90 (-1.28%)
GILD   74.59 (-4.16%)
DIS   118.81 (+1.29%)
NFLX   421.81 (+0.50%)
BAC   24.68 (+2.32%)
Log in

OTCMKTS:OMBPOmni Bio Pharmaceutical Stock Price, Forecast & News

$0.0004
0.00 (0.00 %)
(As of 05/26/2020)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.02
Volume35,000 shs
Average Volume2,020 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-27.97
Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.62 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:OMBP
CUSIPN/A
Phone970-237-5178

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees1
Next Earnings DateN/A
OptionableNot Optionable

Receive OMBP News and Ratings via Email

Sign-up to receive the latest news and ratings for OMBP and its competitors with MarketBeat's FREE daily newsletter.

Omni Bio Pharmaceutical (OTCMKTS:OMBP) Frequently Asked Questions

How has Omni Bio Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Omni Bio Pharmaceutical's stock was trading at $0.0004 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OMBP shares have increased by 0.0% and is now trading at $0.0004. View which stocks have been most impacted by Coronavirus.

Has Omni Bio Pharmaceutical been receiving favorable news coverage?

News stories about OMBP stock have been trending somewhat positive on Monday, InfoTrie reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Omni Bio Pharmaceutical earned a news sentiment score of 1.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutOmni Bio Pharmaceutical.

Who are some of Omni Bio Pharmaceutical's key competitors?

What other stocks do shareholders of Omni Bio Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omni Bio Pharmaceutical investors own include Xenon Pharmaceuticals (XENE), aTyr Pharma (LIFE), Gemini (GKX), Flexion Therapeutics (FLXN), Biocept (BIOC) and Acorda Therapeutics (ACOR).

Who are Omni Bio Pharmaceutical's key executives?

Omni Bio Pharmaceutical's management team includes the following people:
  • Dr. Leland Shapiro M.D., Principal Investigator for Viral & Bacterial Disorders

What is Omni Bio Pharmaceutical's stock symbol?

Omni Bio Pharmaceutical trades on the OTCMKTS under the ticker symbol "OMBP."

How do I buy shares of Omni Bio Pharmaceutical?

Shares of OMBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omni Bio Pharmaceutical's stock price today?

One share of OMBP stock can currently be purchased for approximately $0.00.

What is Omni Bio Pharmaceutical's official website?

The official website for Omni Bio Pharmaceutical is www.omnibiopharma.com.

How can I contact Omni Bio Pharmaceutical?

Omni Bio Pharmaceutical's mailing address is 181 W BOARDWALK DRIVE SUITE 202, FORT COLLINS CO, 80525. The biopharmaceutical company can be reached via phone at 970-237-5178 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.